Use search to browse all 100+ peptides
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Banerjee. Mainak M; Pal. Rimesh R; Pal. Sandip S
This study shows that tirzepatide, especially at higher weekly doses (10‑15 mg), can significantly improve liver fibrosis and help resolve fatty liver disease (MASH), ranking just behind the best drug tested. The benefits are partly driven by weight loss, but tirzepatide also appears to work beyond just shedding pounds.
Hoog. Meredith M MM; Vallarino. Carlos C; Maldonado. Juan M JM; Grabner. Michael M; Teng. Chia-Chen...
In everyday patients with type‑2 diabetes, the drug tirzepatide lowered blood sugar and trimmed body weight more than the already‑popular drug semaglutide, and it did so whether or not people had used similar medicines before.
McGowan. Barbara B; Ciudin. Andreea A; Baker. Jennifer L JL; Busetto. Luca L; Dicker. Dror D; Fr...
The review shows tirzepatide helps adults lose a lot of weight (over 10% of body weight) and improves several health markers like blood sugar, heart failure risk, sleep apnea, and fatty liver disease, making it a strong option for biohackers aiming for better metabolism and longevity.
Costa. Matias M; O'Leary. Sean S; Price. Anthony M AM; Young. Christopher C CC; Srinivasan. Visish M...
A big data study looked at people who took GLP‑1 drugs like tirzepatide after different kinds of stroke or brain bleed. It found they were less likely to die, have repeat bleeding, seizures, or fluid buildup in the brain, and they also had a lower chance of having another stroke in the next one to two years. The safety profile was similar to people not on the drugs.
Hankosky. Emily R ER; Lebrec. Jeremie J; Lee. Clare J CJ; Dimitriadis. Georgios K GK; Jouravskaya. I...
In a three‑year study, people with obesity and pre‑diabetes who took the weekly peptide tirzepatide saw their 10‑year chances of heart disease and diabetes drop a lot, especially at higher doses, while those on placebo actually got riskier.
Krüger. Nils N; Schneeweiss. Sebastian S; Fuse. Kenshiro K; Matseyko. Sofiya S; Sreedhara. Sush...
In people with heart failure that still pumps normally but also have obesity or diabetes, the drugs semaglutide and tirzepatide cut the chance of ending up in the hospital for heart failure or dying by more than 40% compared to a standard diabetes drug. Tirzepatide didn’t show any extra benefit over semaglutide, and both were safe in this real‑world study.
Packer. Milton M; Zile. Michael R MR; Kramer. Christopher M CM; DiMaria. Joseph M JM; Baum. Seth J S...
In a big study, the diabetes drug tirzepatide helped people with obesity and a type of heart failure (HFpEF) live longer and feel better, even if they had diabetes. It cut the risk of heart‑related death or worsening symptoms by about 38% and improved walking distance, quality‑of‑life scores, and heart function. People with diabetes lost a bit less weight than those without, but both groups saw similar drops in belly fat around the heart and in the size of the heart muscle.
Masson. Walter W; Lobo. Martín M; Nogueira. Juan P JP; Barbagelata. Leandro L; Touzas. Pedro P;...
A review of several trials shows that tirzepatide, a drug already known for weight loss, also cuts key inflammation markers in the blood, like hsCRP and IL‑6, across the usual doses (5 mg, 10 mg, 15 mg). This anti‑inflammatory effect appears consistent regardless of who takes it, suggesting an extra health boost beyond just losing weight.
Almansour. Hadi A HA; Thaibah. Hilal A HA; Alfarhan. Moaddey M; Al-Qahtani. Saeed A SA; Khardali. Am...
The study looked at real‑world reports of tirzepatide side effects and found a big rise in dosing mistakes, plus common injection‑site pain and nausea. Most reports came from middle‑aged women in the U.S., and the errors got much more frequent over the last few years.
Burr. Eliza E; Roytman. Maya M; Poirier. Évéline É; Kolbuszewska. Marta M; Pfaus. Jam...
A 44‑year‑old woman with severe, lifelong persistent genital arousal disorder saw her symptoms drop by about 95% just two days after starting tirzepatide, a drug usually used for weight loss. This suggests the medication might calm the brain’s reward circuits that drive the unwanted arousal.
Cerchi. Eduardo E; Santo. Paula Arruda do Espírito PADE; de Oliveira. Mariana Carvalho MC; Jano...
Tirzepatide, a once‑weekly injection, cuts weight dramatically – about 9 kg in people with diabetes and up to 18 kg in those without – while also improving body‑measurements, blood pressure, blood sugar and cholesterol, and it does so with mostly mild side effects.
Heinberg. Leslie J LJ; Lee. Alexandra M AM; Foster. Gary D GD; DiVita. Amy A; Allman. Matthew M; Rot...
A 24‑week telehealth program that gave people tirzepatide (or semaglutide) along with a virtual coaching plan helped participants lose an average of 12% of their body weight, drop their blood pressure, and eat and move better, with fewer side‑effects than typical clinical trials.
Kato. Shunsuke S; Kokita. Ayaka A; Akanuma. Hana H; Iwamura. Shogo S; Takahashi. Yuya Y; Kusumi. Ryo...
Tirzepatide not only drops blood sugar and weight in people with type 2 diabetes, it also makes them feel better about their diet and more satisfied with treatment, even beyond the weight loss effect.
Hannon. Tamara S TS; Chao. Lily C LC; Barrientos-Pérez. Margarita M; Pamidipati. Karthik Chandr...
In a 30‑week trial, tirzepatide dramatically lowered blood sugar (about 2.2% drop in HbA1c) and cut body weight (7‑11% reduction in BMI) in teens with type‑2 diabetes, with effects staying strong for a year. Side effects were mainly mild stomach issues that got better over time, and the safety looked similar to what’s seen in adults.
Oe. Yuki Y; Nomoto. Hiroshi H; Cho. Kyu Yong KY; Omori. Takashi T; Nakamura. Koki K; Takahashi. Akih...
In a small 6‑month study of people with type‑2 diabetes and chronic kidney disease, switching from the GLP‑1 drug dulaglutide to tirzepatide lowered blood‑sugar (HbA1c) and body weight more than staying on dulaglutide, while kidney damage markers stayed steady. Some participants had stomach upset and a few insulin‑using folks experienced low blood‑sugar episodes.
Lee. Byung Wan BW; Lee. Chang Beom CB; Lim. Soo S; Kim. Sin Gon SG; Kim. Nan Hee NH; Won. Jong Chul...
In Korean adults with type 2 diabetes, weekly tirzepatide (5‑15 mg) cut blood‑sugar levels by about 3 % and trimmed body weight by roughly 7‑11 % over 40‑52 weeks, with most people hitting the <7 % HbA1c goal and many reaching ≤6.5 % without gaining weight or severe low‑blood‑sugar episodes. The safety picture matched what’s seen in larger, global studies, so the drug looks both powerful and tolerable for real‑world use.
Kasagga. Alousious A; Rebellow. Delvy D; Hashmi. Tooba T; Husami. Malik Y MY; Lama. Pooja P; Arul Se...
A meta‑analysis of eight trials in non‑diabetic adults with obesity shows tirzepatide leads to greater weight loss than semaglutide, especially at higher doses (15 mg and the maximum tolerated dose), but it also causes more stomach upset and higher dropout rates.
Guan. Haixia H; Jiang. Hongwei H; Yuan. Huijuan H; Sun. Jie J; Xu. Jiawei J; Ji. Linong L
In a 2‑year study, tirzepatide (5‑15 mg weekly) cut blood‑sugar levels far more than insulin glargine and caused big weight loss (about 8‑11 kg) in people with type 2 diabetes who were still uncontrolled on metformin or sulfonylureas. It also led to fewer low‑blood‑sugar episodes and only mild‑to‑moderate stomach side effects.
Hidalgo Ramos. Roberto A RA; Hong. Isaac I; Ortiz. Marcelo M; Secades. Daniela D; Dufner Krieger. Se...
The review shows that tirzepatide helps people lose fat while keeping their muscle mass basically the same, and may even slightly improve muscle quality, making it a useful tool for those looking to slim down without losing strength.
Lin. Pao-Yen PY; Zeng. Bing-Yan BY; Hsu. Chih-Wei CW; Suen. Mein-Woei MW; Hung. Chao-Ming CM; Stubbs...
A big analysis of 55 trials found that the weight‑loss drug tirzepatide may actually lower the chance of getting blood cancers, especially lymphoma, while another drug, dulaglutide, might raise that risk. The study didn’t find any clear cancer risk changes for SGLT2 inhibitor drugs.